Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetrahydrobiopterin (BH₄)
- Target
- BH₄
- Molecular classification
- Small molecule cofactor, Pteridine derivative
01
Overview
Tetrahydrobiopterin (BH₄) is an essential, naturally occurring pteridine cofactor required for the catalytic activity of phenylalanine hydroxylase, as well as other aromatic amino acid hydroxylases. In the hydroxylation reaction, BH₄ donates electrons to facilitate the conversion of phenylalanine to tyrosine—an important step for neurotransmitter biosynthesis. BH₄ stabilizes the structure of phenylalanine hydroxylase and is necessary for proper function; genetic or acquired deficiencies in BH₄ synthesis or recycling lead to hyperphenylalaninemia and related metabolic disorders, most notably phenylketonuria. Synthetic BH₄ (sapropterin) is used pharmacologically to treat certain PKU patients who retain some sensitivity to the cofactor.
- Other names
- BH₄tetrahydrobiopterin6R-tetrahydrobiopterinsapropterindihydrobiopterin
02
Mechanism of action
Sapropterin acts as a pharmacological chaperone and cofactor supplement, stabilizing mutant phenylalanine hydroxylase and promoting catalytic activity in PKU patients
03
Biological functions
Serves as an electron donor during the catalytic conversion of phenylalanine to tyrosine by phenylalanine hydroxylaseCofactor for other aromatic amino acid hydroxylases such as tyrosine hydroxylase and tryptophan hydroxylase
04
Disease associations
Implicated in phenylketonuria (PKU) due to its role in stabilizing/enabling phenylalanine hydroxylase activityDeficiency or improper recycling can lead to various metabolic disorders.
05
Safety considerations
Sapropterin is generally well-tolerated, but care is needed to avoid excess lowering of phenylalanine, which can cause neurological symptoms; monitoring is required
06
Interacting drugs
Sapropterin dihydrochloride
07
Biomarkers
Blood phenylalanine level (used to select PKU patients likely to respond to BH₄ therapy)Response to sapropterin supplementation in genotyped PKU patients
Beyond the preview
Go deeper on Tetrahydrobiopterin (BH₄).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetrahydrobiopterin (BH₄).